The complaint claims that Ardelyx failed to disclose significant payer-related hurdles, including stringent prior authorization and step-edit requirements. These barriers allegedly hindered patient access and slowed new-patient starts, ultimately suppressing the growth of the company’s core products. According to the lawsuit, these omissions resulted in the company overstating its commercial outlook during the specified period.

Investors wishing to participate in the litigation have until November 16, 2026, to request appointment as lead plaintiff. Peretz Bronstein, founding partner of the law firm, noted that the action aims to restore capital and ensure corporate accountability. Affected parties can review the complaint or contact firm representatives Peretz Bronstein or Nathan Miller at 917-590-0911 for further details on the proceedings.